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Abstract
BACKGROUND—BRAF mutation status, and therefore eligibility for BRAF inhibitors, is
currently determined by sequencing methods. We assessed the validity of VE1, a monoclonal
antibody against the BRAF V600E mutant protein, in the detection of mutant BRAF V600E
melanomas as classified by DNA pyrosequencing.
METHODS—The cases were 76 metastatic melanoma patients with only one known primary
melanoma who had had BRAF codon 600 pyrosequencing of either their primary (n=19),
metastatic (n=57) melanoma, or both (n=17). All melanomas (n=93) were immunostained with the
BRAF VE1 antibody using a red detection system. The staining intensity of these specimens was
scored from 0 – 3+ by a dermatopathologist. Scores of 0 and 1+ were considered as negative
staining while scores of 2+ and 3+ were considered positive.
RESULTS—The VE1 antibody demonstrated a sensitivity of 85% and a specificity of 100% as
compared to DNA pyrosequencing results. There was 100% concordance between VE1
immunostaining of primary and metastatic melanomas from the same patient. V600K, V600Q, and
V600R BRAF melanomas did not positively stain with VE1.
CONCLUSIONS—This hospital-based study finds high sensitivity and specificity for the BRAF
VE1 immunostain in comparison to pyrosequencing in detection of BRAF V600E in melanomas.
INTRODUCTION
Forty to sixty percent of all cutaneous melanomas harbor mutations in the BRAF oncogene,
which regulates cellular growth signals.(1, 2) Alterations within BRAF often occur as
somatic point mutations in the activating segment at amino acid 600, with the V600E
alteration resulting in a missense substitution of valine by glutamic acid.(1, 3–5) This
V600E mutation accounts for 69 – 94% of BRAF mutations in melanoma.(1, 6, 7) Two
BRAF inhibitors are FDA approved for treatment of unresectable or metastatic melanoma
patients; vemurafenib in patients with V600E mutant melanoma and dabrafenib in patients
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with a V600E or V600K mutant melanoma.(8–10) Current methods of detection of a BRAF
mutation are DNA-based assays.(11, 12) These methods often take weeks for completion
and require meticulous selection of a specimen with predominantly viable tumor.(12–14)
Treatment with BRAF inhibitors often results in rapid clinical improvement, and a delay in
therapy could be detrimental to patient care.(13)
Treating patients without a known mutation status with BRAF inhibitors carries the risk of
further acceleration of melanoma tumor growth in NRAS mutant cases due to paradoxical
activation of MAPK signaling.(15–18) With the use of current molecular methods, the
potential for enhanced tumor growth must be weighed against harmful delays in treatment.
Recently, a monoclonal antibody against mutant BRAF V600E protein (VE1) has been
developed.(11, 19–22) Initial studies indicate high sensitivity and specificity of this antibody
as compared to DNA sequencing.(11, 14,19–24) Use of immunohistochemistry for VE1
could potentially allow for a quick and efficient method of detection of BRAF mutation
status. In this study, we attempt to validate the VE1 antibody using a different
immunostaining platform and protocol as compared to previous investigators, test the
antibody against different BRAF mutations, measure interobserver differences in scoring
VE1 staining, examine the heterogeneity of VE1 staining within melanomas, and determine
concordance of BRAF V600E status between primary and metastatic lesions.
MATERIALS AND METHODS
Case Selection
Following institutional review board approval, 97 primary and metastatic melanomas were
retrieved from a case series of 79 patients treated at UNC Healthcare with known BRAF
mutational status determined for clinical purposes in the UNC Molecular Genetics
Laboratory using a CLIA-certified method of DNA pyrosequencing.(9, 25) H&E slides from
these cases were reviewed for presence of sufficient tumor. One primary and three
metastatic melanomas were excluded because of insufficient melanoma tissue in the block
for recuts as determined by the study dermatopathologist. The remaining 93 primary and
metastatic melanomas from 76 patients with a sufficient amount of tumor tissue for
immunohistochemistry were analyzed.
Immunohistochemistry
Immunohistochemistry for mutant BRAF V600E protein was performed using the
monoclonal mouse antibody VE1 (Spring Bioscience, Pleasanton, CA). Immunostaining
was performed in the UNC Department of Dermatology Dermatopathology Laboratory. In
this study, all tissue was fixed in neutral buffered formalin purchased commercially. Most
samples had between 6 and 48 hours of total formalin fixation time prior to tissue
processing. Our routine overnight tissue processing cycle includes the following: formalin
for 60 minutes, 70% alcohol for 55 minutes, 95% alcohol for 35 minutes, 95% alcohol for
55 minutes, 100% alcohol for 30 minutes, 100% alcohol for 40 minutes, 100% alcohol for
55 minutes, xylene for 45 minutes, xylene for 55 minutes, paraffin for 30 minutes, paraffin
for 30 minutes, paraffin for 30 minutes, and paraffin for 45 minutes. The original block used
for genetic analysis was accessible and immunostained for all but 3 of the specimens. A
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tissue block adjacent to the original block was chosen for these three specimens. Freshly cut
4-µm thick sections of formalin-fixed and paraffin-embedded melanoma tissue blocks were
stained using the fully automated Leica Bond III system. Pretreatment was performed using
an onboard heat-induced epitope retrieval in EDTA buffer (ER2) for 30 minutes. Incubation
with the VE1 antibody at a 1:100 dilution was done for 30 minutes at room temperature.
Chromogenic detection was performed using the Leica Refined Red polymer detection
system (Leica Microsystems). Incubation with hematoxylin for 10 minutes was used for
counterstaining. Melanomas with documented BRAF mutational status were used as internal
controls.
Pathology scoring
Immunostained slides were subsequently evaluated by a dermatopathologist (D.C.Z.)
blinded to all genetic and clinical data. Specimens were analyzed for their degree of
cytoplasmic immunostaining (0–3+). When cytoplasmic staining was scored as 0 or 1+
(with 1+ representing a weak cytoplasmic blush of staining), cases were scored as negative;
while scores of 2+ and 3+ (indicating strong cytoplasmic staining) were considered positive
results. Additionally, the dermatopathologist commented on whether there was VE1 nuclear
staining independent of cytoplasmic staining. The percent of tumor that stained was also
scored. To measure interobserver differences, a second dermatopathologist (P.A.G) similarly
scored the metastatic melanomas with pyrosequencing results (n=57) independently.
Statistical analysis
The sensitivity and specificity of the VE1 immunostain as compared to DNA
pyrosequencing were determined. A Pearson chi-squared test was used to determine the
relationship of VE1 status with patient sex. An unpaired Student’s t-test was used to
determine the association of VE1 status with age at diagnosis of the primary melanoma. P-




The study included a series of 76 melanoma patients with known BRAF mutational status in
their metastatic or primary melanoma and sufficient tumor for immunostaining with the VE1
antibody. Of these 76 patients, 27 had a BRAF V600E mutation and another 9 had an
alternate BRAF V600 mutation, (V600K, V600R, or V600Q) on initial analysis. Of these
specimens with pyrosequencing results, 19 were primary melanomas while 57 were
metastatic melanomas. The age at diagnosis of the primary melanoma, sex, and AJCC TNM
stage of these patients at the time of pyrosequencing of their melanoma is provided in Table
1. Additionally, 17 patients in this series with sufficient tumor had an additional matched
primary (n=13) or metastatic melanoma (n=4) that was stained for VE1.
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Interobserver Differences of BRAF VE1 Staining and Concordance of VE1
Immunohistochemistry Between Matched Primary and Metastatic Lesions
The kappa statistic for agreement for VE1 positivity between the two dermatopathologists
was 1.00. All 17 matched pairs of metastatic and primary melanomas with sufficient tissue
for immunohistochemistry demonstrated 100% concordance for VE1 staining. Three of
these matched cases had positive immunohistochemistry results while 14 stained negatively.
VE1 Immunohistochemistry Compared with Genetic Analysis and Re-review of
Pyrosequencing on Melanomas with Discrepant Results
According to DNA pyrosequencing, 40 of the 76 cases were determined as BRAF wild type
while 36 cases had a BRAF mutation, comprised of BRAF V600E (n=26), V600K (n=8),
V600R (n=1), or V600Q (n=1) mutations (Table 2). Twenty-two specimens immunostained
positively (scores of 2+ and 3+) for VE1, while 54 specimens immunostained negatively
(scores of 0 and 1+) (Figures 1, 2).
In this study there were 5 (6.6%) discordant cases, all of which were 0 (n=3) or 1+ (n=2) by
VE1 immunostaining but DNA pyrosequencing showed a V600E mutation (Table 2). Three
of the discordant cases were metastatic lesions while the remaining 2 were primary lesions.
Two of the discordant metastatic lesions had a matched primary lesion that was also tested.
In both of those cases, the VE1 immunostain results for the primary and metastatic lesions
were concordant with each other but were discordant with the positive DNA pyrosequencing
result.
The pyrograms and interpretations from the five discrepant cases that were BRAF V600E
mutation positive by pyrosequencing, but negative by IHC, were reviewed. Two of the cases
showed a BRAF V600E mutation at a high allele frequency, and the high level of mutant
DNA was consistent with the high estimated tumor percentage on the reviewed H&E
section. Two of the cases showed a BRAF V600E mutation at an allele frequency lower than
expected, possibly indicating tumor heterogeneity for the mutation. These two cases may
represent true false negatives by IHC or false positives by pyrosequencing. The fifth case
was found on review to contain a BRAF V600K mutation that was originally misinterpreted
as a V600E mutation.
Sensitivity and Specificity
Compared to pyrosequencing (which was used as the gold standard for this study) after
rereview of the discrepant cases, one case was reclassified as V600K rather than V600E.
After reclassification of this case, immunohistochemical analysis with VE1 demonstrated a
sensitivity of 85% (22/26) and a specificity of 100% (50/50) for the BRAF V600E mutation
(Table 3). Specimens with the V600K, V600R, and V600Q mutations were not
immunoreactive with the VE1 antibody.
Heterogeneity of VE1 Staining Within Melanomas
Only 2 specimens were determined to be heterogeneous in immunohistochemical staining.
One of these cases stained 99% of the tumor. Upon initial scoring, the other case was scored
as homogeneously negative; however, upon re-examination, this tumor was determined to be
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10% positive. This specimen was also one of the 5 discordant cases reported, and we did not
change its classification because it was originally scored as negative. No other heterogeneity
in cytoplasmic staining of the melanoma tumor cells was found.
Primary Melanomas
Including the matched pairs, 33 of the 93 specimens with VE1 immunostaining results were
primary melanomas. Ten of these primaries stained positively while 23 stained negatively.
These melanomas varied in stage, site, and classification. In this study, there was positive
staining for superficial spreading (6/12), nodular (2/11), acral lentiginous (1/3), and spitzoid
(1/1) melanoma subtypes. Primary melanoma subtypes tested with negative immunostaining
results included mucosal (n=4), desmoplastic (n=1), and lentigo maligna (n=1) melanoma.
Additionally, primary melanomas of different AJCC clinical stages were tested with the
VE1 antibody. AJCC Stage T1 (0/2), Stage T2 (1/4), Stage T3 (5/9), and Stage T4 (4/18)
melanomas demonstrated positive immunostain results. Primary melanomas with and
without ulceration were used in this study, showing positive immunostaining in ulcerated
(3/17) and non-ulcerated (7/16) melanomas (see Fig. 3).
Metastatic Melanomas
Our results demonstrated associations between immunostaining with VE1 in metastatic
melanomas and certain clinical characteristics. Younger age at diagnosis of the primary
melanoma was found to be associated with increased positive immunostaining (p=0.002).
There was a borderline but non-significant association with sex between positive and
negative VE1 results (p=0.06). Melanoma metastases from a variety of locations were tested
with the VE1 immunostain, with positive results in cutaneous (6/19), lymph node (9/28),
and mucosal (1/4) locations. Other metastases with negative immunostaining results had soft
tissue (n=2), brain (n=2), muscle (n=1), or lung (n=1) location.
DISCUSSION
Our study demonstrated a sensitivity of 85% and a specificity of 100% for the BRAF VE1
immunohistochemistry using a red chromagen as a method of detection of BRAF V600E
mutant protein as compared to DNA pyrosequencing for detection of BRAF V600E mutant
DNA in routinely processed formalin-fixed paraffin-embedded melanoma tumor tissues. No
melanoma with a BRAF V600K, V600R, or V600Q mutation stained with the VE1 antibody.
Also the antibody had little variability in strength or intensity across our 93 specimens. After
gaining experience with the antibody, we noticed that in nearly every case the tumor is
either strongly positive or it is negative/very weak blush. The majority of specimens had
homogeneous VE1 melanoma staining. Our study also demonstrated 100% concordance
between matched primary and metastatic melanomas. We also demonstrated high
interobserver agreement for scoring of the VE1 antibody staining, similar to Marin et al.(26)
We demonstrated the utility of VE1 on a variety of metastatic and primary melanomas,
including different primary melanoma histologic subtypes and metastases from a variety of
cutaneous, lymph node, and visceral locations. Furthermore, the VE1 immunostain was
associated with younger patient age at diagnosis of the primary melanoma, supporting the
association of BRAF mutated melanoma and younger age.(27)
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There are several differences in our methods as compared to most previous investigators.
These include the use of the Mixed Red Refine reagent from Leica Microsystems as
opposed to the Ventana OptiView and Ultraview Universal DAB Detection kits. This
difference allows for improved differentiation of staining in melanoma specimens with a red
chromagen as opposed to a brown chromagen. Additionally, our study is unique in using the
Leica Bond III system as opposed to the Ventana Benchmark system.(11, 19,22, 28, 29)
Other differences in protocol as compared to previous investigators include dilution of the
antibody used, method of epitope retrieval, and time and temperature of incubation with the
immunostain. We used a 1:100 dilution of the antibody, while other studies used higher
concentrations including dilutions of 1:50, 1:5, or undiluted solutions.(11, 19,24, 29) We
also performed epitope retrieval with EDTA for 30 minutes as opposed to Ventana Cell
Conditioning solution for 64 minutes.(24) Additionally, we incubated the antibody for 30
minutes at room temperature as opposed to 37 degrees Celsius for 32 minutes.(11, 19, 29)
Therefore, our study serves to provide additional validation of this antibody with a different
immunostaining platform and protocol.
We used a graded system of staining as a method of assessment, similar to initial studies
(11, 28), to determine the variability in the strength and intensity of VE1 staining. Other
investigators did not use a graded system.(19, 20, 23) Our results showed only occasional
heterogeneity of BRAF VE1 staining, similar to some other studies.(19, 24) Like us, some
previous investigators scored isolated nuclear staining as negative.(19, 20, 24) We
characterized the nuclear staining as part of the process of validating the antibody but did
not find any clinical significance of nuclear staining in retrospective analysis. In accordance
with the antibody specifications sheet, the VE1 immunostain is a cytoplasmic stain,
consistent with BRAF being a cytoplasmic protein.
Our analysis is consistent with prior studies indicating a high sensitivity and specificity of
the VE1 antibody for identifying BRAF V600E mutant melanomas, although some studies
have achieved higher sensitivity (Table 4).(11, 19–22) Several reasons could account for the
differences in sensitivity. Methods of VE1 staining may have played a major role.
Additionally, previous investigators have used different gold standards to determine the
presence of the BRAF mutation. Colomba et al. compared different methods of detection of
BRAF mutations in melanoma specimens and found pyrosequencing to be the most efficient.
We used pyrosequencing as our reference. It is also possible that preanalytical variables
played a part in the discrepancy between our results and previous investigators. However,
our results might also approximate what will be found in widespread clinical practice as
many different labs start offering this test. Commonly, when immunostains are first
published, it is often difficult for subsequent investigators to achieve the same high results as
the initial publications.
Five of our cases were discordant on initial review, where DNA pyrosequencing was
positive for the BRAF V600E mutation but immunostaining of the tissue with the VE1
antibody was negative. However on reanalysis of the pyrosequencing results, one case that
was originally interpreted as V600E was found on review to represent a V600K mutation.
The pyrosequencing assay used in the UNC Clinical Molecular Genetics Laboratory is
designed to quantitatively interrogate mutations at position 1799. While the assay is only
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semiquantitative when applied to tumors with varying amounts of mixed stromal cells, the
percentage of T or A alleles at that position can be estimated. This assay is meant to identify
the V600E c.1799T>A mutation and other clinically important variants at or near nucleotide
position 1799, such as variants at position 1798 or 1800. While surrounding base cells are
represented by peaks on the pyrogram, the level of those nucleotide peaks are not
quantitatively interrogated by the software. The alternate peak patterns may be difficult to
interpret, especially if the mutant allele frequency is low. Previous investigators have also
indicated discrepant results in molecular analysis.(14, 19) While BRAF inhibitors have
demonstrated improved rates of overall and progression-free survival in patients with the
BRAF V600E mutation in a phase 3 randomized clinical trial, some sensitivity has been
shown against other mutations.(30) Of the five discordant cases, only one patient has been
treated with targeted BRAF treatment. This metastatic melanoma patient is currently being
treated with BRAF/MEK combination therapy (dabrafenib and trametinib) and, while
improved since baseline, demonstrates slow progression.
Mismatches between immunohistochemistry and DNA pyrosequencing may also be due to
sampling errors, tissue necrosis, or a decreased sensitivity of immunohistochemistry for the
BRAF mutation. These differential results may also be due to intratumoral heterogeneity
regarding the presence of a BRAF mutation,(31) although the majority of the melanomas in
our study had homogenous VE1 staining. Generally homogenous VE1 staining with
occasional or no heterogeneity in BRAF V600E expression has been demonstrated in
previous studies.(11, 20,22, 32, 33) This heterogeneity has not been shown to correlate with
survival and may be due to pre-analytical factors.(11, 32, 34) Heterogeneity within a tumor
for the presence of the BRAF mutation status must be further studied.
Our results corroborate preservation of the BRAF V600E mutation between paired primary
and metastatic melanomas from the same patient,(35) and we extend these results to
concordance of BRAFV600E at the protein level. These findings are consistent with the
early occurrence of BRAF mutations within melanoma pathogenesis.(35) Additionally, we
show strong VE1 staining of a capsular melanocytic nevus in Figure 1. This finding supports
the presence of BRAF V600E mutant protein in nevi, indicating that BRAF mutations alone
are not sufficient for melanoma pathogenesis.(3) Therefore, this immunostain should not be
considered diagnostic for melanoma. Together, these results suggest that in cases where
metastatic lesions are inaccessible or unavailable, the primary lesion could potentially be
used for testing. In this situation, patients with the BRAF mutation may have improved
access to BRAF inhibitors.
Immunostaining with the VE1 antibody for the BRAF V600E mutation did not produce any
false positive results. This finding combined with the high sensitivity of VE1 for this BRAF
mutation supports the use of an algorithm incorporating both the VE1 antibody and DNA
mutational analysis. In this model, immunohistochemistry initially could be used in patients
with insufficient melanoma tissue for genetic analysis. This subset of patients would
otherwise not be analyzed for the BRAF mutation using existing methods of detection. In
patients with sufficient melanoma tissue, immunohistochemistry first could be used to
quickly and inexpensively detect BRAF V600E mutations. Cases with negative VE1 results
should be tested by a DNA mutational analysis assay to rule out a possible false negative
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result or a different BRAF mutation. The sequential use of these methods should allow for a
highly sensitive and specific detection of the BRAF V600E mutation.(9, 14) Alternatively, if
immunostaining were done in addition to mutational analysis on melanomas, the combined
results might increase overall diagnostic accuracy for V600 mutational subtype if discrepant
cases were reevaluated for their mutational status.
In the era of personalized medicine, BRAF mutation status has become a key piece of
information in the clinical management of melanoma patients. In this study, we found the
VE1 monoclonal antibody as method of detection of the BRAF V600E mutation in our
institution to have high sensitivity and specificity with generally homogenous staining.
Based on these results, immunostaining with the VE1 antibody seems to be an effective and
efficient screening tool in the assessment of BRAF V600E mutant status in melanoma
patients. In addition, VE1 staining seems to be complementary with mutational screening, as
reevaluation of discrepant cases may improve diagnostic accuracy.
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BRAF wild type melanoma in a lymph node that is negative for VE1 immunostain alongside
a 3+ positive capsular melanocytic nevus (Original magnification ×100).
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BRAF wild type melanoma with 1+ weak cytoplasmic and nuclear blush on VE1
immunostain (Original magnification ×200).
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A, BRAF V600E mutant primary melanoma with positive staining for VE1 (×200). B,
Corresponding BRAF V600E metastatic melanoma with positive staining for VE1 in the
same patient (Original magnification ×100).
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Table 1
Patient Case Series
Characteristic Value N (%) VE1+ (%) VE1− (%)
Total patients 76 (100) 22(29) 54(71)





Male 44 (58) 9 (20) 35 (80)
Female 32 (42) 13 (41) 19 (59)
Overall AJCC TNM Stage at Pyrosequencing
I 9 (14) 4 (44) 5 (55)
II 20 (31) 3 (15) 17 (85)
III 33 (51) 12 (36) 21 (64)
IV 3 (5) 0 (0) 3 (100)
DNA Pyrosequencing Results





Melanoma Type Tested for Pyrosequencing
Metastatic 57 (75) 16 (28) 41 (72)
Primary 19 (25) 6 (32) 13 (68)
Primary Location
Skin 16 (84) 6 (38) 10 (63)
Mucosal 3 (16) 0 (0) 3 (100)
Metastatic Location
Skin 19 (33) 6 (32) 13 (68)
Lymph node 28 (49) 9 (32) 19 (68)
Muscosal 4 (7) 1 (25) 3 (75)
Soft tissue 2 (4) 0 (0) 2 (100)
Brian 2 (4) 0 (0) 2 (100)
Muscle 1 (2) 0 (0) 1 (100)
Lung 1 (2) 0 (0) 1 (100)





Staining Intensity scored from 0 to 3+ (0=negative staining, 1+=weak background staining, 2+=moderately positive staining, 3+ strongly positive
staining) with 0 and 1+ considered negative scores and 2+ and 3+ considered positive scores.
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